No misrepresentation of vital status follow-up in PLATO: Predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial-Reference-Cited by-同舟云学术

No misrepresentation of vital status follow-up in PLATO: Predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial

Published:2014-09 Issue:1 Volume:176 Page:300-302
ISSN:0167-5273
Container-title:International Journal of Cardiology
language:en
Short-container-title:International Journal of Cardiology

Author:

Wallentin Lars,Becker Richard C.,Cannon Christopher P.,Held Claes,Himmelmann Anders,Husted Steen,James Stefan K.,Katus Hugo A.,Mahaffey Kenneth M.,Pieper Karen S.,Storey Robert F.,Steg Philippe Gabriel,Harrington Robert A.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference7 articles.

1. Ticagrelor versus clopidogrel in patients with acute coronary syndromes;Wallentin;N Engl J Med,2009

2. Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome

3. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)

4. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation;Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)1;Eur Heart J,2012

5. 2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antiplatelet agents for chronic kidney disease;Cochrane Database of Systematic Reviews;2022-02-28

2. Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: insights from the randomised GLOBAL LEADERS trial;EuroIntervention;2019-12

3. Impact of tailored anti-P2Y12 therapies in acute coronary syndromes;Pharmacogenomics;2015-04

4. Ticagrelor: A Review of Its Use in Adults with Acute Coronary Syndromes;American Journal of Cardiovascular Drugs;2015-02